Rachel Chihana

Rachel Chihana

Auto-generated profile, based on publicly available information

Rachel Chihana

Kamuzu University of Health Sciences-Johns Hopkins Research Project, Blantyre 312223, Malawi

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2024 in Vaccine
Verified
Journal Article
Open access
RCRachel Chihana
Rachel Chihana
JKJia Jin Kee
Jia Jin Kee
ZMZoe Moodie
Zoe Moodie
YHYunda Huang
Yunda Huang
HJHolly Janes
Holly Janes
FLFatima Laher
Fatima Laher
Background: Reactogenicity informs vaccine safety, and may influence vaccine uptake. We evaluated factors associated with reactogenicity in HVTN 702, a typical HIV vaccine efficacy trial with multiple doses and products. Methods: HVTN 702, a phase 2b/3 double-blind placebo-controlled trial, randomized 5404 African participants aged 18-35 years without HIV to placebo, or ALVAC-HIV (vCP2438) at months 0, 1 and ALVAC-HIV (vCP2438) + Bivalent Subtype C gp120/MF59 at months 3, 6, 12 and 18. Using multivariate logistic regression, we evaluated associations between reactogenicity with clinical, sociodemographic and laboratory variables. Results: More vaccine than placebo-recipients reported local symptoms (all p < 0.001), arthralgia (p = 0.008), chills (p = 0.012) and myalgia (p < 0.001). Reactogenicity was associated with female sex at birth (ORv = 2.50, ORp = 1.81, both p < 0.001) and geographic region. Amongst vaccine-recipients, each year of age was associated with 3 % increase in reactogenicity (OR = 1.03, p = 0.002). Conclusion: Vaccine receipt, female sex at birth, older age, and region may affect reactogenicity.

16 June 2023 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
RCRachel Chihana
Rachel Chihana
CKChaplain Katumbi
Chaplain Katumbi
SDSufia Dadabhai
Sufia Dadabhai
AKAgness Kaumba
Agness Kaumba
AMAtusaye Mughogho
Atusaye Mughogho
KMKen Malisita
Ken Malisita
Malawi HIV treatment guidelines recommend same-day antiretroviral therapy (ART) initiation. Overall 97.9% of Malawians living with HIV (PLHIV) are on ART, same-day ART initiation prevalence and factors that facilitate it have not been fully described. We assessed same-day ART initiation and described individual, health system and health facility infrastructural factors at health facilities supported by expert clients (EC). ECs are lay PLHIV who support other PLHIV. The study was conducted in urban and semi-urban primary health facilities, in Blantyre, Malawi. It was a cross-sectional, descriptive survey of PLHIV and health facility leaders. Eligibility criteria included age ≥ 18 years, new diagnosis of HIV, received counselling from ECs, and offered same-day ART. The study was conducted from December 2018 to June 2021, and 321 study participants enrolled. Mean age (standard deviation) was 33 years (10) with 59% females. In total, 315 (98.1%) initiated same-day ART. Four participants did not because of mental unpreparedness, one wanted to try herbal medicine and one was concerned about stigma related to taking ART. Participants reported health facility accessibility (99%, 318/321), privacy (91%, 292/321) and quality of counselling by EC as excellent (40%, 128/321). Same-day ART was nearly universal. Participants’ satisfaction with health services delivery, the presence of EC, and infrastructural characteristics such as adequate privacy were cited as reasons favoring same-day linkage to ART. The most cited reason for not starting same-day ART was mental unpreparedness.

6 May 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
AKAlka Khaitan
Alka Khaitan
JLJane C. Lindsey
Jane C. Lindsey
ECEdmund V. Capparelli
Edmund V. Capparelli
CTCamlin Tierney
Camlin Tierney
ACAnne Coletti
Anne Coletti
SPSallie Permar
Sallie Permar
Antiretroviral therapy (ART) in infancy restricts the HIV-1 reservoir but is insufficient for ART-free remission. We hypothesized that broadly neutralizing antibodies (bNAbs) administered at the initiation of ART would be safe and reduce HIV-1 DNA in peripheral blood cells more than ART alone. In a randomized, open-label two-arm study of infants with HIV-1 within 14 days of ART initiation, 30 infants received subcutaneous VRC01 (40 milligrams per kilogram), a bNAb that targets the CD4-binding site of gp120, at weeks 0, 2, 6, and 10, whereas 31 participants received no VRC01. VRC01 was well tolerated with no safety concerns. Decreases in HIV-1 DNA from weeks 0 to 14 were not different between arms overall nor when adjusted for a priori–defined covariates, including baseline resistance to VRC01. Baseline VRC01 resistance and resistance to prescribed ART were detected in a subset of infants treated with VRC01. Plasma VRC01 trough concentrations were below those predicted by pretrial modeling based on studies of infants exposed but uninfected with HIV-1. No anti-VRC01 antibodies were detected to account for low VRC01 concentrations. In post hoc analyses, higher plasma HIV-1 RNA values correlated with lower plasma VRC01 concentrations, whereas larger reductions in HIV-1 DNA were associated with higher VRC01 concentrations and lower plasma HIV-1 RNA, suggesting a concentration-dependent effect of bNAb treatment on HIV-1 DNA. These results highlight the safety of bNAbs for treatment of infants. Studies with more potent bNAbs are needed to assess effects on HIV-1 DNA during early treatment of infants living with HIV-1.

9 December 2022 in medRxiv
Verified
Preprint
Open access
PDF file
RCRachel Chihana
Rachel Chihana
CKChaplain Katumbi
Chaplain Katumbi
SDSufia Dadabhai
Sufia Dadabhai
AKAgness Kaumba
Agness Kaumba
AMAtusaye Mughogho
Atusaye Mughogho
KMKen Malisita
Ken Malisita
Malawi HIV treatment guidelines recommend same-day antiretroviral therapy (ART) initiation. Overall 97.9 % of Malawians living with HIV (PLHIV) are on ART, same-day ART initiation prevalence and factors that facilitate it have not been fully described. We assessed same-day ART initiation and described individual, health system and health facility infrastructural factors at health facilities supported by expert clients (EC). ECs are lay PLHIV who support other PLHIV. The study was conducted in urban and semi-urban primary health facilities, in Blantyre, Malawi. It was a cross-sectional, descriptive survey of PLHIV and health facility leaders. Eligibility criteria included age ≥ 18 years, new diagnosis of HIV, received counselling from ECs, and offered same day ART. The study was conducted from December 2018 to June 2021, and 321 study participants enrolled. Mean age (standard deviation) was 33 years (10) with 59% females. In total, 315 (98.1%) initiated same day ART. Four participants did not because of mental unpreparedness, one wanted to try herbal medicine and one was concerned about stigma. Participants reported health facility accessibility (99%,318/321), privacy (91%, 292/321) and quality of counselling by EC as excellent (40%,128/321). Same day ART was nearly universal. Participants’ satisfaction with health services delivery, the presence of EC, and infrastructural characteristics such as good privacy were cited as reasons favoring same day linkage to ART. The most cited reason for not starting same day ART was mental unpreparedness.

23 April 2026
Verified
Dataset
Closed access
UGUdayan Gupta
Udayan Gupta
RKRachel Chihana Kawalazira
Rachel Chihana Kawalazira
SDSufia Dadabhai
Sufia Dadabhai
BioStudies – one package for all the data supporting a study